Straumann Holding AG (STMN) AI Stock Analysis

• Market Cap: CHF16.33B
• Dividend Yield: 0.93%
• Average Volume (3M): 273.27K
• Price to Earnings (P/E): 42.2
• Beta (1Y): 1.40
• Revenue Growth: 3.82%
• EPS Growth: 57.08%
• Country: CH
• Employees: 11,342
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Instruments & Supplies
• EPS (TTM): N/A
• Shares Outstanding: 159,455,250
• 10 Day Avg. Volume: 310,459
• 30 Day Avg. Volume: 273,275
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: CHF137.67
• Price Target Upside: 34.44% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 6

• Rating: 73 Outperform
• Price Target: CHF110.00 ▲(7.42% Upside)

Straumann Holding AG presents a strong financial foundation and positive earnings outlook driven by strategic growth initiatives and innovation. However, technical indicators suggest short-term bearish trends, and the high P/E ratio indicates potential overvaluation risks.

Positive Factors

Earnings

The company reported a strong start with top-line results beating expectations, indicating robust growth.

Market Performance

Asia Pacific achieved a historical high in revenue with significant growth, driven by strong market performance.

Product Development

Product cadence and market feedback on iEXCEL were comforting, suggesting sequential improvement.

Negative Factors

Market Environment

Macro and consumer picture in the US has worsened, potentially affecting Straumann's performance.

Regional Performance

There is concern over sequentially slower North American growth and a lack of clarity on aligner products.

Regional Volatility

US remains a vulnerability in the medium term, with greater volatility likely to affect the outlook.

Straumann Holding AG Business Overview & Revenue Model

Company Description

Straumann Holding AG provides tooth replacement and orthodontic solutions worldwide. It researches, develops, manufactures, and supplies dental implants, instruments, CADCAM prosthetics, orthodontic aligners, biomaterials, and digital solutions for use in tooth correction, replacement, and restoration, as well as to prevent tooth loss. The company offers dental implant systems for tissue and bone level; titanium, titanium alloy, ceramic, and mini dental implant systems; and guided and non-guided surgical instruments, as well as implant-borne prosthetics. It provides ceramic healing and screw retained abutments; intraoral scanning solutions; 3D printers; milling machines; and prevention products. In addition, it offers biomaterials, bone substitutes, membranes, biologics, and soft tissue management and oral healing products; digital solutions for dental labs, dentists, and centralized milling centers, as well as materials, third party systems, and guided surgery; surgical instruments comprising surgical and modular cassettes, guided instruments, implant maintenance products, bone block fixation sets, bonerings, titanium pin sets, and other cassettes; and edentulous, pro arch fixed, prosthetic, and mini implant solutions for edentulous patients. Further, it provides esthetic restorations that include ceramic implant monotypes, ceramic implants, abutments, biologics, and other solutions; and Emdogain for wound healing. Further, it offers systems Clear Correct aligners; and training and education services to its customers. The company provides its products to general dentists, specialists, and dental technicians and laboratories, as well as corporate customers, such as distributors, hospitals, universities, and dental service organizations in approximately 100 countries through a network of distribution subsidiaries and partners. Straumann Holding AG was founded in 1954 and is headquartered in Basel, Switzerland.

How the Company Makes Money

Straumann Holding AG generates revenue primarily through the sale of dental implants and prosthetic products. The company also earns income from its digital dentistry solutions, which include CAD/CAM systems, intraoral scanners, and 3D printing technologies. Additionally, Straumann offers regenerative products, such as biomaterials for oral tissue regeneration. The company collaborates with dental professionals and institutions globally, leveraging significant partnerships and distribution networks to expand its market reach. Factors such as a growing global demand for dental care, advancements in dental technology, and an aging population contribute to the company's earnings. Straumann's strategic acquisitions and investments in innovative technologies further bolster its revenue streams.

Straumann Holding AG Financial Statement Overview

Summary

Straumann Holding AG is in a strong financial position, with consistent revenue growth and profitability. The company maintains a healthy balance sheet with manageable debt levels. Cash flow is stable, supporting future growth. However, attention should be given to rising operational costs and liabilities.

Income Statement

Straumann Holding AG has demonstrated consistent revenue growth with a solid increase from 2023 to 2024. Gross Profit Margin is strong, indicating effective cost management. However, there is a slight decline in EBIT and EBITDA margins, suggesting rising operating costs or increased competition.

Balance Sheet

The company's balance sheet is stable with a moderate Debt-to-Equity ratio, reflecting balanced leverage. The Return on Equity is healthy, indicating efficient use of equity. The Equity Ratio is solid, showing a strong financial position, although the increase in total liabilities warrants monitoring.

Cash Flow

The cash flow is robust with a stable Free Cash Flow, reflecting the company's good cash generation capacity. There is a slight decline in Operating Cash Flow, which could be a sign of higher operational expenses. The Free Cash Flow to Net Income ratio is favorable, indicating efficient cash management.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.50B	2.41B	2.32B	2.02B	1.43B
Gross Profit	1.78B	1.79B	1.70B	1.53B	1.03B
EBITDA	726.15M	685.07M	685.37M	591.48M	230.45M
Net Income	388.32M	246.07M	434.79M	396.08M	91.28M
Balance Sheet
Total Assets	3.62B	3.40B	3.45B	3.05B	2.62B
Cash, Cash Equivalents and Short-Term Investments	383.07M	413.54M	697.11M	881.50M	632.49M
Total Debt	413.89M	412.35M	705.20M	711.66M	731.66M
Total Liabilities	1.58B	1.56B	1.60B	1.55B	1.41B
Stockholders Equity	2.04B	1.84B	1.85B	1.50B	1.20B
Cash Flow
Free Cash Flow	315.62M	316.61M	220.94M	440.97M	295.34M
Operating Cash Flow	483.39M	503.95M	416.38M	561.94M	377.41M
Investing Cash Flow	-352.62M	-349.33M	-449.84M	-185.20M	-145.64M
Financing Cash Flow	-169.06M	-424.40M	-140.35M	-122.90M	153.33M

Straumann Holding AG Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 102.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:STMN, the sentiment is Negative. The current price of 102.4 is below the 20-day moving average (MA) of 105.21, below the 50-day MA of 105.35, and below the 200-day MA of 111.88, indicating a bearish trend. The MACD of -0.69 indicates Positive momentum. The RSI at 43.58 is Neutral, neither overbought nor oversold. The STOCH value of 36.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:STMN.

Straumann Holding AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
STMN	73 Outperform	CHF16.33B	42.22		0.93%	3.82%	57.08%
SOON	61 Neutral	CHF12.69B	24.32		1.99%	6.58%	-10.02%
Sector *	50 Neutral	AU$2.60B	3.64	-58.14%	2.69%	36.37%	13.78%
ALC	―	$42.18B	37.16	5.23%	0.39%	―	―
TCHBF	―	$2.46B	31.98	4.84%	1.64%	―	―
0QLQ	―	CHF5.20B	59.27	13.49%	0.55%	―	―
GALD	71 Outperform	CHF30.24B	92.13		0.12%	6.22%	―

Straumann Holding AG Corporate Events

Straumann Group Announces Webcast for Half-Year Results 2025

Straumann Holding AG announced a webcast for their half-year results 2025, scheduled for August 13, 2025. The event targets investors, financial analysts, and media professionals, providing insights into the company’s business development and offering a platform for questions and answers with the management. This announcement highlights Straumann’s commitment to transparency and engagement with stakeholders, potentially impacting investor confidence and market perception.

The most recent analyst rating on (CH:STMN) stock is a Hold with a CHF143.00 price target. To see the full list of analyst forecasts on Straumann Holding AG stock, see the CH:STMN Stock Forecast page.

Straumann Announces Major Investment in Villeret Amid Strategic Shift to China

Straumann Holding AG has announced a strategic investment of 60 to 80 million CHF in its Villeret site over the next five years to enhance its role as a competence center for innovation and precision manufacturing. This investment will focus on advanced technologies and infrastructure modernization, while also addressing workforce adjustments due to the relocation of production for the Chinese market to a new campus in Shanghai. The move aims to secure competitiveness in China, which accounts for over 15% of Straumann’s global revenue, and ensure long-term growth and market positioning. The changes could affect up to 250 positions in Villeret, with a consultation process underway to explore socially acceptable solutions.

The most recent analyst rating on (CH:STMN) stock is a Buy with a CHF157.00 price target. To see the full list of analyst forecasts on Straumann Holding AG stock, see the CH:STMN Stock Forecast page.